Perfusion-based mAb production at 250 mL scale using ATF technology

Perfusion processes have become increasingly important for manufacturing monoclonal antibodies (mAbs) because they can sustain higher cell densities, extend production runs, and boost volumetric productivity. In this GEN webinar, Vivian Ott, a process intensification specialist, will present data demonstrating how a small-scale mAb perfusion process using the Sartorius Ambr® 250 Modular—a bioreactor not designed for perfusion—and the Repligen single-use XCell® ATF 1 Device can yield comparable outcomes to large-scale bioreactors. She will show how a continuous mAb production process, run over 23 days, achieved a volumetric productivity of 0.65 g/L/day. Attendees will also hear from Repligen’s Béla Brühlmann, who will introduce the benefits of upstream process intensification and how the XCell ATF increases productivity and reduces cost of goods from early development through commercial-scale GMP manufacturing. Key takeaways from the webinar include: - Why small-scale perfusion models are critical for process development and seed train intensification - How XCell® ATF technology enables increased productivity and greater efficiency - How the linear scalability of the XCell® ATF System ensures manufacturability from process development to commercial scale